Aveanna Healthcare (NASDAQ:AVAH) Given New $9.50 Price Target at Barclays

Aveanna Healthcare (NASDAQ:AVAH) had its price objective upped by Barclays from $9.00 to $9.50 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms also recently commented on AVAH. BMO Capital Markets cut their target price on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Stephens upgraded Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Truist Financial boosted their price objective on shares of Aveanna Healthcare from $8.00 to $9.00 and gave the company a “hold” rating in a report on Wednesday, May 20th. Finally, Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Aveanna Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $10.56.

Aveanna Healthcare Price Performance

Shares of NASDAQ AVAH opened at $9.82 on Thursday. The firm has a market cap of $2.14 billion, a P/E ratio of 8.32, a PEG ratio of 0.95 and a beta of 1.89. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 5.35. Aveanna Healthcare has a twelve month low of $3.73 and a twelve month high of $10.32. The company has a 50 day moving average of $7.60 and a 200 day moving average of $7.58.

Aveanna Healthcare (NASDAQ:AVAH) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.05. The firm had revenue of $647.91 million for the quarter, compared to the consensus estimate of $613.22 million. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%.The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. As a group, research analysts expect that Aveanna Healthcare will post 0.68 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Robert M. Williams, Jr. sold 3,000,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total transaction of $24,030,000.00. Following the completion of the transaction, the insider owned 190,130 shares in the company, valued at approximately $1,522,941.30. The trade was a 94.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder J.H. Whitney Equity Partners V sold 2,419,035 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $8.01, for a total value of $19,376,470.35. Following the transaction, the insider directly owned 10,112,123 shares of the company’s stock, valued at approximately $80,998,105.23. This represents a 19.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 31,305,664 shares of company stock valued at $215,555,910 in the last 90 days. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Aveanna Healthcare

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Aveanna Healthcare by 38.0% in the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after buying an additional 1,535,351 shares during the last quarter. Geode Capital Management LLC boosted its stake in Aveanna Healthcare by 17.7% in the fourth quarter. Geode Capital Management LLC now owns 1,849,057 shares of the company’s stock valued at $15,110,000 after acquiring an additional 278,429 shares in the last quarter. Nuveen LLC boosted its stake in Aveanna Healthcare by 135.9% in the fourth quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock valued at $12,838,000 after acquiring an additional 905,316 shares in the last quarter. State Street Corp grew its holdings in shares of Aveanna Healthcare by 20.9% during the fourth quarter. State Street Corp now owns 1,483,265 shares of the company’s stock worth $12,118,000 after purchasing an additional 256,392 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Aveanna Healthcare by 49.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock worth $8,593,000 after purchasing an additional 441,707 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.